December 3, 2019 (Carthage, MO USA) Stratum Nutrition®, the Global Leader of eggshell and eggshell membrane wellness ingredients, and President, Micah Osborne, announce, “NEM® has become an internationally recognized joint health ingredient as supported in a large, double-blind, placebo-controlled Clinical Trial from Turkey.”
The Journal of Arthritis (J Arthritis 8(4):285.) recently published a large independent multi-center, randomized double-blind, placebo-controlled trial evaluating the efficacy of Stratum’s flagship ingredient, NEM® brand eggshell membrane, in 166 subjects diagnosed with Grade 2 or Grade 3 osteoarthritis of the knee.
This study was conducted at eight different university medical centers in Turkey and confirmed NEM®’s fast results in only 7 days. By Day 30, both knee pain and stiffness had improved by more than 30% in the NEM® -treated subjects. This study also employed a unique blinded, single-crossover design to compare subjects taking NEM® for 90 days versus subjects taking NEM® for 60 days (the former placebo subjects who began taking NEM® after Day 30). A responder analysis found a statistically significant difference between the number of patients having at least a 15% decrease in pain, which was greater in the 90-day NEM® group (71% of subjects) compared to the 60-day NEM® group (53% of subjects).
“This is the largest study conducted to date involving NEM® and we are pleased that it was supportive of its fast time to efficacy, even in subjects with moderate to severe arthritis. This, combined with its cartilage protecting effects recently demonstrated in healthy individuals, makes NEM® the perfect adjunctive therapy for those with joint issues,” stated Kevin J. Ruff Ph.D., MBA – Sr. Director of Scientific & Regulatory Affairs for Stratum Nutrition.